Novo and Abingworth led a £90m Series A round in Myricx Bio.

Novo and Abingworth, two life science investors, led a £90m Series A round in Myricx Bio, with participation from British Patient Capital, Cancer Research Horizons, Lilly, Brandon Capital and Sofinnova Partners. “Myricx has gained unique insights into the biology of NMT and its orthogonal and differentiated mechanism. The scientific rationale behind its novel payload chemistry gives us confidence that NMTi-ADCs have the potential to greatly expand the current repertoire of ADC applications beyond the current standard-of-care payload classes, creating opportunities for new treatment options for patients. This investment reflects our strategy of investing in highly innovative and high impact biotechs, and we look forward to supporting the progress of Myricx through the clinic,” Michael Bauer, Novo Partner.